8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 18, 2025

Silence Therapeutics plc

(Exact name of Registrant as Specified in Its Charter)


England and Wales	001-39487	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

12 Hammersmith Grove London United Kingdom		W6 7AP
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: +44 20 3457 6900

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing 3 ordinary shares, nominal value £0.05 per share	SLN	The Nasdaq Stock Market LLC
Ordinary share, nominal value £0.05 per share*	*	The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of New Executive Director

On December 18, 2025, the Board of Directors (the “Board”) of Silence Therapeutics plc (the “Company”) appointed Rhonda Hellums, the Company’s Executive Vice President and Chief Financial Officer, to the Board, effectively immediately. In accordance with the Company’s articles of association, Ms. Hellums will serve for an initial term expiring at the end of the Company’s 2026 Annual General Meeting of Shareholders. As an executive director, Ms. Hellums will not be appointed to serve on any committee of the Board.

As an executive director, Ms. Hellums will not receive additional compensation for her service as a member of the Board.

There is no arrangement or understanding between Ms. Hellums and any other person pursuant to which Ms. Hellums was selected as a director of the Company, and there is no family relationship between Ms. Hellums and any of the Company’s other directors or executive officers. Ms. Hellums does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K. Ms. Hellums’s biography is set forth in the Company’s definitive proxy statement for its 2025 Annual General Meeting of Shareholders filed with the Securities and Exchange Commission on May 16, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Silence Therapeutics plc

Date: December 22, 2025	By:	/s/ Rhonda Hellums
		Name: Rhonda Hellums
		Title: Chief Financial Officer

SEC Form 8-K filed by Silence Therapeutics Plc